Alzheimer’s Therapeutics Market size is anticipated to reach USD 6.4 billion in 2024. Alzheimer’s disease is a progressive, non-reversible, and neurodegenerative disorder. Alzheimer is caused due to abnormal functioning of brain cells. It is the most common form of dementia. In simple words, it is a biological disease marked by physical changes in the brain and most remarkably build-up of small protein clumps called “Tangles” and “Plaques” that lead to the death of nerve cells.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/alzheimers-therapeutics-market/request-sample
The key driving factors responsible for the growth of Alzheimer’s
Therapeutics market :
The factors that propel the
growth of the Alzheimer’s therapeutics market include well-developed healthcare
infrastructure, high consciousness levels, increase in incidence of
neurodegenerative diseases, growing aged population, and increasing R&D
investment. On the other hand, there are factors that may hamper the growth of
the market including lack of transparent reimbursements, high cost of treatment
and diagnosis in the later stage, typically owing to delayed appearance of
symptoms.
The new product launches and
research collaborations are some of the key strategies adopted by the top
industry players. For instance, Actavis plc in collaboration with Adamas
Pharmaceuticals Inc. lately publicized the US FDA approval of Namzaric, a
fixed-dose combination of donepezil and memantine. The drug is likely to be
launched in the first half of year 2015. Additionally, in Jan 2015, Johnson
& Johnson signed a research deal with a Swiss biotech firm AC Immune, to
change anti-tau Alzheimer's vaccines.
Alzheimer’s therapeutics industry
is anticipated to expand at a significant CAGR in the upcoming period as the
scope, product types, and its applications are increasing across the globe.
Alzheimer’s therapeutics market could be explored by therapeutic type,
application and geography. The market could be explored by therapeutic type as
N-methyl-D-aspartate (NMDA) receptor antagonist and Cholinesterase Inhibitors.
The “Cholinesterase Inhibitors” segment led the Alzheimer’s therapeutics
industry in 2016 and is anticipated to maintain its dominance by 2024. The key
applications that could be explored in the Alzheimer’s therapeutics market
include Moderate to severe Stages, and Early to Moderate Stages.
North America accounted for the
major share of the Alzheimer’s therapeutics industry in 2016 and will continue
to lead in the forecast period. The factors that could be attributed to the
growth include increasing prevalence of Alzheimer’s disease, growing aged
population, extensive technological advancements in the region, high awareness
levels, and strong healthcare infrastructure. North America is likely to be
followed by Europe.
View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/alzheimers-therapeutics-market
No comments:
Post a Comment